RU2345763C1 - Method for reduction and prevention of cardiovascular by-effects induced by application of phosphodiesterase type 5 inhibitors for treatment of erectile dysfunction in men - Google Patents

Abstract

FIELD: medicine; sexual pathology.

SUBSTANCE: prevention of cardiovascular by-effects induced by introduction of phosphodiesterase type 5 inhibitors for treatment of erectile dysfunction in men is ensured with introduction of one preparation from the specified group: Sildenafil citrate dosed 25-100 mg, or Vardenafil hydrochloride dosed 5-20 mg, or Tadalafil dosed 20 mg, combined with introduction of De-Nol dosed 1 tablet.

EFFECT: improved microcirculation due to higher synthesis of endogenous prostaglandins and prevented cardiovascular by-effects induced by introduction of specified preparations, improved erection in present category of patients.

1 ex

Description

The invention relates to medicine, namely to sexopathology.

Currently the most common methods for treating erection disorders in men using drugs from the group of type 5 phosphodiesterase inhibitors: sildenafil citrate (25-100 mg), vardenafil hydrochloride (5-20 mg) and tadalafil (20 mg) situationally before intercourse (The Russian Drugs Register “Encyclopedia of Medicines”, Moscow, 2006, pp. 162, 724, 761) have a wide variety of side effects - headache, dizziness, sleep disturbance, flushing, blurred vision, nasal congestion, ringing tinnitus nziya, tachycardia, dry mouth, nausea, heartburn, gastritis, which limits their application.

There is a method of stopping and preventing side cardiovascular events by prescribing various symptomatic therapeutic agents, as well as reducing their dose (Russian Drug Register "Encyclopedia of Medicines", M., 2006, p.725).

The disadvantage of these methods is their low efficiency, which limits the use of type 5 phosphodiesterase inhibitors, which are currently the most effective for the treatment of erection disorders in men.

The technical result of the proposed solution is the relief and prevention of adverse cardiovascular events with the use of type 5 phosphodiesterase inhibitors, which helps to expand the possibility of using these drugs, as well as increase the effectiveness of treatment.

This result is achieved by the fact that, in addition to the type 5 phosphodiesterase inhibitors (sildenafil citrate 25-100 mg or vardenafil hydrochloride 5-20 mg or tadalafil 20 mg), de nol is prescribed in a dose of 1 table. once at a time.

This result does not follow from the prior art.

The method is as follows.

Emerging cardiovascular side effects in the treatment of patients with erectile dysfunction with drugs of the 5th type phosphodiesterase group - sildenafil citrate 25-100 mg at a time or vardenafil hydrochloride 5-20 mg at a time, or tadalafil 20 mg at a time 1-2 hours before the alleged intercourse, stop the additional simultaneous administration of the drug "De-nol" in a dose of 1 table. once at a time.

Example 1

Patient A., born in 1960, medical history No. 104/06, suffers from erectile dysfunction for more than 10 years. Repeatedly sought sexological help. Acceptance of drugs traditionally used in sexual practice (adaptogens, vitamins, etc.) did not give a positive result. Taking sildenafil citrate at a dose of 25 mg before intercourse did not lead to an improvement in erection and was accompanied by side effects in the form of a headache, a feeling of a rush of blood to the head, face, heart palpitations and dry mouth. Taking sildenafil citrate at a dose of 50 mg improved the quality of an erection, but failed to have an intercourse due to side effects in the form of a severe headache, a feeling of a rush of blood to the head, face, nasal congestion, tinnitus, visual impairment, heart palpitations, dry mouth, nausea and heartburn. At night, the patient could not fall asleep. Similar phenomena were observed with tadalafil at a dose of 20 mg per dose and vardenafil hydrochloride at a dose of 10 mg per dose. Taking drugs below the indicated doses did not give a positive effect. The patient was recommended, when these side effects occur, additionally simultaneously with phosphodiesterase type 5 inhibitors to take de-nol in a dose of 1 table. at the reception once. After adding de-nol, along with a satisfactory erection, the disappearance of side cardiovascular events was noted - headache, a rush of blood to the head, face, tinnitus, visual impairment, heart palpitations, which allowed the patient to have a successful sexual intercourse. Similar results were obtained with tadalafil at a dose of 20 mg per dose or vardenafil hydrochloride at a dose of 10 mg per dose 1-2 hours before the intended sexual intercourse with the additional simultaneous use of de-nol in a dose of 1 table. at the reception once.

Duration of observation - 6 months. The patient took this combination of drugs with a frequency of 1-2 times a week, which allowed for successful sexual intercourse.

This method was applied by us to 17 patients with a positive effect in 76.4% of cases.

This method has advantages over the known ones, consisting in stopping and preventing side cardiovascular events, improving the tolerance of type 5 phosphodiesterase inhibitors used to treat erectile dysfunction in men, which helps to increase the therapeutic effect of this patient population.

Claims (1)

A method for preventing adverse cardiovascular events with the introduction of sildenafil citrate 25-100 mg, or vardenafil hydrochloride 5-20 mg, or tadalafil 20 mg by the simultaneous administration of de-nol in a dose of 1 tablet.